How to Cure Melanoma: Surgery, Immunotherapy & More

Curing melanoma depends almost entirely on when it is caught and how far it has spread. Melanoma discovered early and confined to the skin is usually cured with surgery alone, with five-year survival rates above 99 percent for the thinnest tumors. Once melanoma reaches lymph nodes or distant organs, the picture changes dramatically, but a revolution in immunotherapy and targeted drugs over the past decade means that even some patients with advanced disease achieve durable remissions lasting years. Understanding the full landscape of treatments, from the initial surgery to experimental vaccines, helps explain what “cure” realistically means at each stage.

Surgery as the Foundation

For most people diagnosed with melanoma, the first and most important treatment is cutting the tumor out with a margin of healthy skin around it. How wide that margin needs to be has been studied extensively. Multiple randomized trials, involving thousands of patients collectively, have compared narrow margins of one to two centimeters with wider margins of three to five centimeters. The consistent finding is that wider cuts do not improve survival, disease-free survival, or recurrence rates compared with narrower excisions.¹ A more recent meta-analysis of seven randomized trials confirmed this and added a practical detail: narrow margins significantly reduce the need for complex wound reconstruction, meaning less scarring and faster recovery, with no trade-off in cancer outcomes.² Current guidelines generally recommend margins of one centimeter for thin melanomas and two centimeters for thicker ones.

Beyond removing the primary tumor, surgeons often need to know whether the cancer has spread to nearby lymph nodes. Sentinel lymph node biopsy, a procedure used in melanoma care for nearly three decades, identifies the first lymph node to which a tumor would drain and removes it for examination.³ The procedure is generally recommended for melanomas thicker than one millimeter. For very thin melanomas under 0.8 millimeters without ulceration, the risk of spread is low enough that the biopsy is not routinely done. Between 0.8 and 1.0 millimeters, or when ulceration is present, it becomes a conversation between patient and surgeon about the potential benefits versus the small surgical risk.⁴ A positive sentinel node result does not automatically trigger removal of all nearby lymph nodes; for patients with only a tiny amount of cancer in the sentinel node, careful monitoring with imaging is now considered a reasonable alternative.

Immune Checkpoint Inhibitors

Melanoma was one of the first cancers where immunotherapy proved transformative, and checkpoint inhibitors remain the backbone of treatment for disease that has spread beyond what surgery can handle. The immune system normally uses “brakes” to prevent T cells from attacking the body’s own tissue. Melanoma cells exploit those brakes to hide from immune detection. Drugs that block two of these checkpoints, CTLA-4 and PD-1, release the brakes at different points in the immune response. CTLA-4 acts early, governing T-cell activation in lymph nodes, while PD-1 operates later, suppressing T cells in the tissues where they encounter the tumor.⁵ Because these checkpoints work through distinct mechanisms, blocking both simultaneously can produce a stronger anti-tumor response than targeting either alone.

The landmark trial of combined nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in advanced melanoma demonstrated this clearly. At five years of follow-up, just over half of patients receiving the combination were still alive, compared with about a quarter of those treated with ipilimumab alone. Patients on nivolumab alone fell in between, with a five-year survival rate of 44 percent. The median overall survival for the combination group exceeded five years, a result that would have been unimaginable a decade earlier.⁶ Longer follow-up data suggest that patients who remain in remission at the five-year mark rarely relapse, bringing the concept of functional cure within reach for a meaningful fraction of advanced melanoma patients.

The trade-off is side effects. Combination immunotherapy unleashes the immune system broadly, not just against the tumor, leading to inflammatory reactions that can affect virtually any organ. These immune-related adverse events range from mild skin rashes and fatigue to serious inflammation of the colon, liver, lungs, or endocrine glands. Roughly two-thirds of patients on the combination experience side effects graded as moderate to severe.⁷ Most are managed with corticosteroids, tapered gradually over four to six weeks. For severe reactions that do not respond to steroids, additional immunosuppressive drugs may be needed, though there is evidence that escalating immunosuppression beyond steroids can itself worsen survival outcomes, so clinicians try to use the minimum necessary.⁸ Permanent hormone replacement is sometimes required when the immune system damages the thyroid or pituitary gland, but these endocrine side effects are considered manageable.⁹

A Newer Checkpoint Target Called LAG-3

Not every patient responds to PD-1 and CTLA-4 blockade, and researchers have been looking for additional immune brakes to release. LAG-3 is a third checkpoint molecule found on exhausted T cells, and blocking it alongside PD-1 has emerged as a promising strategy. The combination of relatlimab (anti-LAG-3) and nivolumab roughly doubled progression-free survival compared to nivolumab alone in untreated advanced melanoma, with a median of about ten months versus under five months.¹⁰ This combination was approved in 2022 and offers an alternative for patients who might not tolerate the heavier side-effect burden of ipilimumab-nivolumab.

Laboratory studies have shed some light on how LAG-3 blockade works at the cellular level. When combined with PD-1 inhibition, it appears to shift exhausted T cells toward a more active, tumor-killing state. Interestingly, one of the strongest effects seems to involve natural killer cells rather than T cells alone, especially in patients who respond well to treatment.¹¹ Whether this NK cell activation explains the clinical benefit is still being studied, but it highlights how checkpoint blockade reshapes the immune response in ways that are not fully understood.

Targeted Therapy for BRAF-Mutant Melanoma

About half of cutaneous melanomas carry a mutation in a gene called BRAF, which drives cancer growth through a specific signaling pathway. Drugs that block BRAF produce rapid tumor shrinkage in these patients, often within weeks. The problem is that tumors treated with a BRAF inhibitor alone tend to find workarounds and start growing again. Adding a second drug that blocks MEK, the next step in the same signaling chain, slows that resistance. The combination of dabrafenib and trametinib, for instance, produced a response in roughly two-thirds of patients compared with about half on dabrafenib alone, with slightly longer progression-free survival.¹²

Even with combination targeted therapy, resistance develops in the majority of patients, typically around one year.¹³ About a fifth of patients never respond at all due to intrinsic resistance.¹⁴ The tumors re-activate the same signaling pathway through various molecular escape routes, or switch to entirely different growth pathways. This resistance problem is why targeted therapy and immunotherapy are increasingly being used together or sequenced strategically rather than relying on one approach alone.

Giving Immunotherapy Before Surgery

One of the more exciting shifts in melanoma care has been the move toward giving immunotherapy before surgery, not just after it. The logic is straightforward: when the tumor is still in the body, it provides a target for the immune system to learn from. Activating the immune response while the tumor is present may create stronger and more durable immunity than waiting until after the tumor has been removed.

The SWOG S1801 trial tested this by giving patients with surgically removable stage III or IV melanoma either pembrolizumab before and after surgery, or only after surgery. The difference was striking. Two-year event-free survival was 72 percent in the group that received neoadjuvant (pre-surgery) treatment compared with 49 percent in the surgery-first group.¹⁵ A separate trial, NADINA, using ipilimumab plus nivolumab before surgery, showed a similar advantage, with one-year event-free survival of about 84 percent versus 57 percent for adjuvant-only nivolumab.¹⁶ These results are reshaping standard practice for high-risk, surgically removable melanomas. Many oncology centers now offer neoadjuvant immunotherapy as a preferred approach rather than going straight to the operating room.

Tumor-Infiltrating Lymphocyte Therapy

For patients whose melanoma has progressed through checkpoint inhibitors and targeted therapy, options were historically grim. TIL therapy changed that calculation. The approach involves surgically removing a piece of the tumor, extracting the immune cells already inside it, growing billions of those cells in a laboratory, and then infusing them back into the patient. The FDA approved lifileucel, the first commercially available TIL product, for advanced melanoma in 2024.¹⁷

In clinical trials, about a third of patients who had already failed both checkpoint inhibitors and targeted therapies responded to lifileucel, and roughly 80 percent achieved at least disease stabilization.¹⁸ In a pooled analysis, the median duration of response had not been reached even after more than two years of follow-up, meaning many responders continued to benefit for an extended period. The overall response rate in the pooled analysis was about 31 percent, with some patients achieving complete remission.¹⁹ The treatment is intensive, requiring hospitalization, chemotherapy to prepare the body, and close monitoring, but it represents a genuinely new option for patients who have exhausted other treatments.

Oncolytic Virus Therapy

Talimogene laherparepvec, usually called T-VEC, is a genetically modified herpes virus injected directly into melanoma tumors. The virus preferentially infects and kills cancer cells while also stimulating the immune system, both at the injection site and potentially at distant tumor sites.²⁰ Clinical trials demonstrated a meaningful durable response rate and a trend toward better overall survival compared with a control treatment.²¹ In single-institution experience, nearly half of treated patients achieved a complete response, suggesting the drug works well for the right candidates, particularly those with injectable skin or lymph node tumors rather than deeply internal disease.²² T-VEC is generally well tolerated, with side effects typically limited to flu-like symptoms after injection.

Personalized Cancer Vaccines

Perhaps the most forward-looking treatment under development is a personalized mRNA cancer vaccine. The concept borrows from the mRNA platform used for COVID-19 vaccines but tailored to each patient’s tumor. After surgery, the tumor is sequenced to identify mutations unique to that patient’s cancer, and a custom vaccine is manufactured to train the immune system to recognize those specific mutations.

A phase II trial tested the combination of one such vaccine, called mRNA-4157/V940, with pembrolizumab in patients with high-risk resected melanoma. Patients who received the vaccine-plus-pembrolizumab combination had a meaningfully lower recurrence rate compared with those on pembrolizumab alone.²³ The results, while from a relatively small trial, generated significant excitement and the vaccine has advanced to phase III testing.²⁴ If the larger trials confirm the early findings, personalized vaccines could become a standard add-on to checkpoint inhibitors for patients at high risk of recurrence after surgery.

When Melanoma Reaches the Brain

Melanoma has a particular tendency to spread to the brain, and brain metastases remain one of the most challenging complications. Stereotactic radiosurgery, which delivers highly focused radiation to individual brain tumors, has become the preferred approach because it avoids the cognitive damage associated with whole-brain radiation. Emerging evidence suggests that combining stereotactic radiosurgery with immunotherapy produces better results than either alone. Patients receiving concurrent immunotherapy and radiosurgery were significantly more likely to achieve a complete or partial response and less likely to experience tumor progression.²⁵

Timing matters, too. One study found that patients who received immunotherapy within a week of radiosurgery had a three-year survival rate of 55 percent, compared with 35 percent for those who started immunotherapy more than a week later.²⁶ The synergy likely works because radiation-induced tumor cell death releases molecules that help prime the immune system, and having checkpoint inhibitors on board at that moment amplifies the effect. Researchers are also exploring whether radiation doses can be lowered when patients are on immunotherapy, since the immune boost may compensate for a smaller radiation dose while reducing the risk of radiation-related brain injury.²⁷

Tracking Response With Circulating Tumor DNA

One of the practical challenges in melanoma treatment is knowing whether a therapy is working before imaging scans can show a difference, or knowing after surgery whether microscopic disease remains. Circulating tumor DNA, fragments of cancer DNA shed into the bloodstream, is increasingly being used as a real-time biomarker. In advanced melanoma, the level of circulating tumor DNA correlates with tumor volume and can distinguish responders from non-responders during treatment, while also flagging resistance mechanisms as they develop.²⁸

For patients who have had melanoma surgically removed but are at high risk of recurrence, detecting circulating tumor DNA after surgery indicates that hidden disease is likely still present. In one large study, patients who tested positive for circulating tumor DNA before starting adjuvant immunotherapy had roughly double the risk of recurrence compared with those who tested negative.²⁹ Longitudinal tracking of circulating tumor DNA levels also correlates with what imaging eventually shows, making it a promising tool for catching recurrence earlier than a scheduled CT scan would.³⁰ This technology is not yet standard everywhere, but it is moving rapidly toward routine clinical use.

Melanoma Subtypes That Play by Different Rules

Not all melanomas are created equal. The treatments discussed above were largely developed for cutaneous melanoma, the common sun-related type. Acral melanoma (on the palms, soles, and nail beds) and mucosal melanoma (inside the mouth, nose, or genital tract) are biologically distinct and generally respond less well to checkpoint inhibitors. They carry different genetic mutations, with KIT mutations found in up to about 36 percent of acral melanomas and 39 percent of mucosal melanomas, far more frequently than in typical sun-related melanomas.³¹ These subtypes also tend to behave more aggressively overall.³² While patients whose tumors carry KIT or BRAF mutations can benefit from targeted drugs, most acral and mucosal melanoma patients lack common driver mutations and have limited genotype-specific treatment options.³³

Uveal melanoma, which arises in the eye, is another subtype with its own treatment landscape. It rarely responds to standard checkpoint inhibitors. In 2022, tebentafusp became the first drug to demonstrate an overall survival benefit in uveal melanoma. It works through a unique mechanism: an engineered T-cell receptor that recognizes a specific protein on tumor cells, fused to a component that activates nearby T cells to kill those tumor cells.³⁴ The catch is that tebentafusp only works in patients who carry a particular immune tissue type called HLA-A*02:01, which is present in roughly half of people of European descent and less common in other populations.³⁵ For eligible patients, it represents a breakthrough; for those without the right tissue type, the search continues.

How Gut Bacteria Influence Treatment Outcomes

A less intuitive factor in melanoma treatment success is what lives in your gut. Research has established that the composition of a patient’s gut microbiome can influence whether checkpoint inhibitors work or fail. In a study of melanoma patients receiving anti-PD-1 therapy, those who responded to treatment had significantly greater diversity in their gut bacteria and higher levels of specific bacterial families compared to non-responders. When stool from responding patients was transplanted into germ-free mice, those mice showed enhanced anti-tumor immune responses.³⁶

This finding has raised questions about whether diet and supplements could be used to optimize the microbiome before or during immunotherapy. Early research suggests that dietary fiber may play a role, though the relationship between probiotics, diet, and checkpoint inhibitor response is still being worked out.³⁷ Some researchers have cautioned that commercially available probiotic supplements may not help and could even be counterproductive by reducing microbial diversity. Clinical trials of fecal microbiota transplants in melanoma patients who initially failed immunotherapy are underway, and early results have been encouraging enough to keep the field moving forward. For now, there is no specific microbiome-based prescription, but the connection between gut health and cancer immunotherapy response is one of the more intriguing areas of active investigation.